Metrics as of 10/17/2026, 07:12 AM (Berlin time), refresh in progress.
Impact BioMedical Stock
Impact BioMedical Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Frank D. Heuszel
- Employees
- 2
- Market cap
- $23 M
- IPO
- 16/09/2024
Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule…
Impact BioMedical stock: price history
1D
-15.2%
1W
-36.9%
1M
-57.3%
6M
-67.1%
YTD
-57.9%
1Y
-64.7%
2Y
-85.5%
5Y
–
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~16% weaker price swings than usual
Ask the agents about Impact BioMedical
Impact BioMedical stock metrics
P/E
-2.18
P/B
2.13
EV/EBITDA
-57.07
RETURN ON EQUITY
-6.5%
NET MARGIN
-23,300.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.5%
FLOAT SHARES
8,503,993
AVG. DAILY VOLUME (30D)
24,239
Insider transactions (SEC)
DSS, INC.
DSS, INC.
DSS, INC.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Impact BioMedical stock
What does Impact BioMedical do?
Impact BioMedical Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Frank D. Heuszel, the company employs around 2 people.
The IPO was on 16/09/2024; the stock trades on AMEX under the ticker IBO.
When does Impact BioMedical report next?
Around past earnings, price swings were roughly -16% stronger than usual.
Does Impact BioMedical pay a dividend?
No, Impact BioMedical currently does not pay a dividend.
Which stocks are comparable to Impact BioMedical?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Impact BioMedical stock analyzed?
Clicking "Analyze stock" lets five strategies assess Impact BioMedical against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.